The TRAb human 1 Step RIA is used for the quantitative determination of Thyrotropin (TSH) receptor autoantibodies in human serum for the diagnostics of autoimmune diseases of thyroid gland.
The majority of TSH receptor autoantibodies (TRAb) mimic the action of TSH on thyroid cells and thus increase blood levels of T4 and T3.
Due to absence of a negative feedback system, the stimulation of the thyroid gland often leads to the clinical thyrotoxic state of Graves’ disease.
Consequently, the measurement of TRAb is valuable for the differential diagnosis of hyperthyroidism as well as for the followup of Graves' disease, both during and after its treatment by antithyroid drugs, radioiodine therapy or surgery.
Pregnant women developing Graves' disease can transfer their autoantibodies to the fetus via the placental unit.
The higher the TRAb concentrations of the mother, the greater the risk for the embryo to develop Graves' disease in uterus and thus to suffer from congenital hyperthyroidism.